F-Prime is a global venture firm investing across healthcare and technology, with a strategy centered on backing technically differentiated companies attacking large, complex markets. The firm is willing to take meaningful early risk, but only when strong domain expertise, credible validation, and a clear commercialization path support the opportunity.
Evaluation weights
How much weight this investor places on each dimension. Totals 100%.
Revenue, growth, and unit economics
Size, timing, and competitive landscape
Founder experience and execution ability
Differentiation and technical quality
- Bias toward vertical, domain-specific solutions over broad horizontal narratives
- Bias toward measurable proof over sector hype
- Willingness to accept technical risk when commercial path is credible
- Preference for regulated-market infrastructure with durable defensibility
Pitch difficulty
How hard it is to get a meeting and close funding from this investor.
Deals closed in a typical year.
Rounds led in the last 12 months.
Decks reviewed in a typical year.
Share of pitches that get funded.
Estimated — public data is not fully disclosed.
- Strong emphasis on domain-expert founders and execution history
- Requires tangible validation such as pilots, revenue traction, or clinical data
- Avoids hype-driven markets without clear commercial proof
- Looks for step-change product or scientific differentiation, not incremental stories
F-Prime is open across multiple stages and will back early risk, but the bar is high on founder credibility, evidence of validation, and a concrete path to commercialization. Companies in speculative or weakly validated sectors are unlikely to advance.
Green flags
What drives a yes for this investor.
- Founders with deep domain expertise and a demonstrated execution track record
- Quantifiable market pain with clear ROI or clinical relevance
- Early validation such as pilot customers, enterprise usage, pre-clinical data, or milestone attainment
- Differentiated technical, product, or scientific advantage with defensible IP or workflow fit
- A credible go-to-market and commercialization path in a large market
Red flags
What kills deals and gets a fast no.
- No clear go-to-market path or vague commercialization plan
- Pitching a hype-heavy category without revenue, adoption, or clinical proof
- Incremental science or product improvement without step-change impact
- Founders lacking domain depth for a specialized or regulated market
- Technical ambition disconnected from customer ROI or clinical outcomes
How to win
Patterns that lead to successful pitches.
- Lead with founder-market fit and why this team is uniquely qualified
- Show quantified proof: pilots, enterprise usage, ROI, clinical data, or milestone attainment
- Make the commercialization path explicit, including buyer, workflow, and regulatory strategy
- Frame the company as a vertical or infrastructure solution in a large, inefficient market
- Demonstrate disciplined capital use and a credible path to scalable economics
Fund strategy & identity
Who they are and how they operate.
- Invests from Pre-Seed through Growth, with strongest activity from Seed to Series B
- Leads or co-leads rounds with conviction, especially at Seed and Series A
- Balances technical risk against commercial risk rather than avoiding risk outright
- Backs both life sciences platforms and applied technology infrastructure
- Uses larger checks where early proof and category potential justify ownership
Investment focus
Industries, themes, and typical ARR expectations.
Investment thesis
Core beliefs and strategy behind their investing approach.
Decision patterns
How they evaluate and make investment decisions.
Notable investments
Key portfolio companies and why they fit the thesis.
Key people
Partners who lead investments and shape the thesis.
Public voice
Notable statements and public positions.
Similar investors
Firms with overlapping stage and industry focus.
